Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
GGAU 0.190 +0.0% KIRO 0.640 +0.0% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.100 +0.0% SHL 0.360 +1.4% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.38 −1.3% CAM 0.330 −1.5% SYH 0.395 −2.5% LOT 0.040 +0.0% CPL 0.180 −5.3% OTMC 0.410 +2.5% PEX 0.180 −2.7% GGAU 0.190 +0.0% KIRO 0.640 +0.0% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.100 +0.0% SHL 0.360 +1.4% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.38 −1.3% CAM 0.330 −1.5% SYH 0.395 −2.5% LOT 0.040 +0.0% CPL 0.180 −5.3% OTMC 0.410 +2.5% PEX 0.180 −2.7%
Production / Operations

TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida

By The Northwire Desk — AI Analysis Dec 17, 2025 · 17:01 VIVI · 0.74 TempraMed Technologies Ltd.
VIVI · Price

Executive Summary

  • TempraMed Technologies Ltd. opened an additional manufacturing facility in Florida, expanding its U.S. production footprint.
  • The new site increases capacity for core products (VIVI Cap™, VIVI Epi™) and upcoming offerings (VIVI Box™), aiming to meet rising B2B demand and shorten delivery timelines.
  • Localized production is expected to reduce cost of goods sold (COGS) through improved logistics, lower import reliance, and advanced manufacturing processes, strengthening the company’s commercialization strategy and supply‑chain resilience.

Key Details

  • Location & Purpose: New U.S. manufacturing site in Florida to support high‑volume production of existing and upcoming temperature‑stable medication storage devices.
  • Capacity Expansion: Facility expands operational capacity, enabling faster delivery, tighter quality control, and greater supply‑chain flexibility for U.S. customers.
  • Cost Reduction: Anticipated reduction in COGS via streamlined logistics, reduced import dependencies, and optimized manufacturing workflows.
  • Product Coverage: Supports VIVI Cap™, VIVI Epi™ and the forthcoming VIVI Box™ smart‑storage platform.
  • Strategic Impact: Enhances redundancy and scalability of TempraMed’s global manufacturing network; positions the company to capture growing B2B demand from healthcare providers, pharmacies, payors, and device manufacturers.
  • Market Outlook: Company expects continued growth in demand for temperature‑sensitive medication solutions, including GLP‑1 therapies, biologics, and self‑injectables.

Notable Quotes

  • “Opening a new manufacturing site marks a major step in strengthening our U.S. presence and ensuring we can meet the accelerating needs of healthcare providers, pharmacies, payors, and strategic partners,” – Ron Nagar, CEO
  • “Expanding our U.S. manufacturing footprint strengthens every part of our business—commercialization, cost structure, and customer satisfaction,” – Ron Nagar, CEO
Read the original news release →

More from TempraMed Technologies Ltd.

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 26, 2026 · 16:11

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 22, 2026 · 11:58

TempraMed Technologies Ltd.

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property